NYSE:BSXBoston Scientific Stock Price, Forecast & News

$36.83

+1.70 (+4.84 %)

(As of 04/10/2020 08:16 AM ET)

Add

Compare

Today's Range

$34.99

Now: $36.83▼

$37.24

50-Day Range

$25.83

MA: $34.26▼

$43.02

52-Week Range

$24.10

Now: $36.83▼

$46.62

Volume19.10 million shs

Average Volume15.20 million shs

Market Capitalization$51.42 billion

P/E Ratio11.06

Dividend YieldN/A

Beta0.92

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Beat the Market (BTM) Rank^™

3.6 Analyst's Opinion

Consensus Rating
Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 18 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.01, Boston Scientific has a potential upside of 24.9% from its current price of $36.83.
Amount of Analyst Coverage
Boston Scientific has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Boston Scientific has received 857 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Boston Scientific has received 733 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Boston Scientific has received 53.90% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote “Outperform” if you believe BSX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Boston Scientific does not currently pay a dividend.
Dividend Growth
Boston Scientific does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,427,599.00 in company stock.
Percentage Held by Insiders
Only 0.70% of the stock of Boston Scientific is held by insiders.
Percentage Held by Institutions
91.79% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Boston Scientific are expected to grow by 20.53% in the coming year, from $1.51 to $1.82 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Boston Scientific is 11.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 12.55.
Price to Earnings Ratio vs. Sector
The P/E ratio of Boston Scientific is 11.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.25.
Price to Earnings Growth Ratio
Boston Scientific has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Boston Scientific has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.95 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:BSX

Previous Symbol

CUSIP10113710

CIK885725

Webhttp://www.bostonscientific.com/

Phone508-683-4000

Debt

Debt-to-Equity Ratio0.62

Current Ratio0.97

Quick Ratio0.64

Price-To-Earnings

Trailing P/E Ratio11.06

Forward P/E Ratio24.39

P/E Growth2.33

Sales & Book Value

Annual Sales$10.74 billion

Price / Sales4.79

Cash Flow$2.52 per share

Price / Cash Flow14.62

Book Value$9.96 per share

Price / Book3.70

Profitability

EPS (Most Recent Fiscal Year)$1.58

Net Income$4.70 billion

Net Margins43.78%

Return on Equity21.15%

Return on Assets8.47%

Miscellaneous

Employees36,000

Outstanding Shares1,396,190,000

Market Cap$51.42 billion

Next Earnings Date4/29/2020 (Confirmed)

OptionableOptionable

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock been impacted by COVID-19 (Coronavirus)?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BSX shares have increased by 8.8% and is now trading at $36.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Boston Scientific?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 18 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Boston Scientific.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, April 29th 2020. View our earnings forecast for Boston Scientific.

How can I listen to Boston Scientific's earnings call?

Boston Scientific will be holding an earnings conference call on Wednesday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) posted its earnings results on Wednesday, February, 5th. The medical equipment provider reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.02. The medical equipment provider had revenue of $2.91 billion for the quarter, compared to the consensus estimate of $2.92 billion. Boston Scientific had a net margin of 43.78% and a return on equity of 21.15%. Boston Scientific's revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.39 earnings per share. View Boston Scientific's earnings history.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its FY20 earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of $1.74-1.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.79.

What price target have analysts set for BSX?

21 brokers have issued 12 month price targets for Boston Scientific's stock. Their forecasts range from $30.00 to $58.00. On average, they anticipate Boston Scientific's share price to reach $46.01 in the next year. This suggests a possible upside of 24.9% from the stock's current price. View analysts' price targets for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

1. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company up front cash and commercial-based milestones. Vertiflex’s Superion system is a minimally invasive device to treat patients with lumbar spinal stenosis (LSS). BSX expects the deal to be immaterial to its adjusted EPS through 2020 and accretive thereafter. While we are a little surprised to see BSX enter the spinal surgery market, there probably are synergies with its existing pain business and we see this deal as a typical BSX transaction in which it acquires an asset allowing it to go deeper within a disease state/disorder (in this case chronic pain). We expect BSX’s string of acquisitions over the past ~18 months (including Vertiflex) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating." (5/13/2019)
2. BTIG Research analysts commented, "$42 Story BSX results fell short of Street expectations on a myriad of items. Heading into the print, investors anticipated the paclitaxel and mesh issues but less selling days, a temporary supply issue and a weaker Neuromod result pressured Q1 incrementally. As we anticipated in our preview, BSX guided FY19 revenue growth to the bottom half of the prior range (7-8% from 7- 9%). We revised our estimates accordingly for known pressure points and while there could be upside from high-growth segments (Structural Heart remains likely), our view is that NT significant outperformance by BSX is less likely than it was six months ago. On lower forecasts and a slightly lower multiple, we trim our PT from $45 to $42. Some investors have asked if the growth acceleration story is over. We do not think so but we do think there will be a NT slowdown before potential acceleration." (4/25/2019)

Has Boston Scientific been receiving favorable news coverage?

News headlines about BSX stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Boston Scientific earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutBoston Scientific.

Who are some of Boston Scientific's key competitors?

Some companies that are related to Boston Scientific include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Varian Medical Systems (VAR) and Hologic (HOLX).

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Bank of America (BAC), Walt Disney (DIS), AT&T (T), Visa (v), salesforce.com (CRM), CVS Health (CVS), Micron Technology (MU) and Netflix (NFLX).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:

Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)
Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)
Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)
Mr. David A. Pierce, Exec. VP & Pres of MedSurg (Age 55)
Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), IFM Investors Pty Ltd (0.01%), Gradient Investments LLC (0.01%), Paragon Advisors LLC (0.00%), Private Trust Co. NA (0.00%) and IBM Retirement Fund (0.00%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori. View institutional ownership trends for Boston Scientific.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd, Private Trust Co. NA, and M&G Investment Management Ltd.. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, Wendy Carruthers, and Xin Warren Wang. View insider buying and selling activity for Boston Scientific.

Which major investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including Gradient Investments LLC, State of Alaska Department of Revenue, IBM Retirement Fund, McGuire Investment Group LLC, Paragon Advisors LLC, Modus Advisors LLC, CHICAGO TRUST Co NA, and Legacy Bridge LLC. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu, and Williamson Scott. View insider buying and selling activity for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $36.83.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $51.42 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe. View additional information about Boston Scientific.

What is Boston Scientific's official website?

The official website for Boston Scientific is http://www.bostonscientific.com/.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff